5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.37▼ | 1.36▼ | 1.36▼ | 1.34▲ | 1.31▲ |
MA10 | 1.37▼ | 1.35▲ | 1.35▲ | 1.32▲ | 1.34▲ |
MA20 | 1.36▲ | 1.35▲ | 1.35▲ | 1.30▲ | 1.41▼ |
MA50 | 1.35▲ | 1.34▲ | 1.33▲ | 1.33▲ | 1.91▼ |
MA100 | 1.34▲ | 1.32▲ | 1.31▲ | 1.39▼ | 2.04▼ |
MA200 | 1.33▲ | 1.31▲ | 1.33▲ | 1.85▼ | 1.99▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▲ | 0.001▲ | 0.001▲ | 0.011▲ | 0.030▲ |
RSI | 51.487▲ | 53.679▲ | 55.395▲ | 55.328▲ | 42.855▼ |
STOCH | 66.667 | 80.152▲ | 76.263 | 64.967 | 30.757 |
WILL %R | -50.000 | -33.333 | -33.333 | -13.333▲ | -64.321 |
CCI | 30.688 | 70.603 | 95.131 | 144.712▲ | -35.328 |
Tuesday, June 10, 2025 06:06 AM
Galectin Therapeutics will host a virtual KOL event on MASH cirrhosis and portal hypertension featuring expert presentations and Q&A. Galectin Therapeutics Inc. announced a virtual key opinion ...
|
Monday, June 09, 2025 05:00 PM
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal ...
|
Thursday, May 15, 2025 12:59 AM
NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 1.35 | 1.38 | 1.33 | 1.37 | 188,102 |
12/06/25 | 1.35 | 1.38 | 1.32 | 1.34 | 100,482 |
11/06/25 | 1.33 | 1.39 | 1.31 | 1.32 | 94,225 |
10/06/25 | 1.325 | 1.39 | 1.30 | 1.35 | 172,026 |
09/06/25 | 1.34 | 1.35 | 1.2804 | 1.32 | 166,007 |
06/06/25 | 1.30 | 1.36 | 1.29 | 1.32 | 242,977 |
05/06/25 | 1.28 | 1.32 | 1.27 | 1.30 | 185,892 |
04/06/25 | 1.28 | 1.33 | 1.275 | 1.28 | 93,815 |
03/06/25 | 1.32 | 1.33 | 1.28 | 1.29 | 132,720 |
02/06/25 | 1.29 | 1.37 | 1.28 | 1.29 | 184,273 |
|
|
||||
|
|
||||
|
|